anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
2.1 Important Preparation and Administration Instructions

For intravenous use only. Do not administer intramuscularly or subcutaneously. Never add mannitol in whole blood for transfusion.

Do not administer unless solution is clear and container is undamaged. Discard unused portion. Do not administer 25% mannitol if the fliptop vial seal is not intact.

Additives may be incompatible. Consult with pharmacist, if available.

Do not place 25% Mannitol Injection in polyvinylchloride (PVC) bags; a white flocculent precipitate may form from contact with PVC surfaces. Parenteral drug products should be inspected visually for particulate matter and discoloration whenever container and solution permit.

2.2 Recommended Dosage

Reduction of Intracranial Pressure and Brain Mass

In adults a dose of 0.25 to 2 g/kg body weight as a 15% to 25% solution administered over a period of 30 to 60 minutes; pediatric patients 1 to 2 g/kg body weight or 30 to 60 g/m2 body surface area over a period of 30 to 60 minutes. In small or debilitated patients, a dose of 500 mg/kg may be sufficient. Careful evaluation must be made of the circulatory and renal reserve prior to and during administration of mannitol at the higher doses and rapid infusion rates. Careful attention must be paid to fluid and electrolyte balance, body weight, and total input and output before and after infusion of mannitol. Evidence of reduced cerebral spinal fluid pressure must be observed within 15 minutes after starting infusion.

Reduction of Intraocular Pressure

In adults a dose of 0.25 to 2 g/kg body weight as a 15% to 25% solution administered over a period of 30 to 60 minutes; pediatric patients 1 to 2 g/kg body weight or 30 to 60 g/m2 body surface area over a period of 30 to 60 minutes. In small or debilitated patients, a dose of 500 mg/kg may be sufficient. When used preoperatively, the dose should be given one to one and one-half hours before surgery to achieve maximal reduction of intraocular pressure before operation.

Measurement of Glomerular Filtration Rate (GFR)

100 mL of a 20% solution (20 g) should be diluted with 180 mL of sodium chloride injection (normal saline) or 200 mL of a 10% solution (20 g) should be diluted with 80 mL of sodium chloride injection (normal saline). The resulting 280 mL of 7.2% solution is infused at a rate of 20 mL per minute. The urine is collected by catheter for a specific period of time and analyzed for mannitol excreted in mg per minute. A blood sample is drawn at the start and at the end of the time period and the concentration of mannitol determined in mg/mL of plasma. GFR is the number of mL of plasma that must have been filtered to account for the amount excreted per minute in the urine. Normal clearance rates are approximately 125 mL/minute for men; 116 mL/minute for women.
Necrosome activation following TLR- or cytokine receptor-signaling results in cell death by necroptosis which is characterized by the rupture of cell membranes and the consequent release of intracellular contents to the extracellular milieu. While necroptosis exacerbates various inflammatory diseases, the mechanisms through which the inflammatory responses are regulated are not clear. We show that the necrosome activation of macrophages results in an upregulation of various pathways, including the mitogen-activated protein kinase (MAPK) cascade, which results in an elevation of the inflammatory response and consequent expression of several cytokines and chemokines. Programming for this upregulation of inflammatory response occurs during the early phase of necrosome activation and proceeds independently of cell death but depends on the activation of the receptor-interacting protein kinase-1 (RipK1). Interestingly, necrosome activation also results in an upregulation of IFNβ, which in turn exerts an inhibitory effect on the maintenance of inflammatory response through the repression of MAPK-signaling and an upregulation of Zfp36. Activation of the interferon-induced gene factor-3 (ISGF3) results in the expression of ZFP36 (TTP), which induces the post-transcriptional degradation of mRNAs of various inflammatory cytokines and chemokines through the recognition of AU-rich elements in their 3'UTR. Furthermore, ZFP-36 inhibits IFNβ-, but not TNFα- induced necroptosis. Overall, these results reveal the molecular mechanism through which IFNβ, a pro-inflammatory cytokine, induces the expression of ZFP-36, which in turn inhibits necroptosis and halts the maintenance of the inflammatory response.
OBJECTIVE: To explore the clinical application value of the Bleeding Scoring Scales (2019 Pediatric ITP Scale) in the diagnosis and treatment of children with primary immune thrombocytopenia (ITP).
METHODS: A total of 422 children with ITP were evaluated with the 2019 Pediatric ITP Scale and the 2013 ITP-BAT and their clinical data were analyzed. The correlation between the two bleeding scoring scales and disease stage, platelet count was analysed, the evaluation time, consistency of the two bleeding scoring scales was compared, and the correlation of the two methods. The changes of platelet count and the score of 2019 Pediatric ITP Scale before treatment and after treatment at 48 h and one week were analyzed to detect responsiveness of the 2019 Pediatric ITP Scale.
RESULTS: The score of the 2019 Pediatric ITP Scale was mainly one point and two points, the corresponding bleeding was skin and mucosal bleeding.404 patients (95.7%) had bleeding manifestations, including 249 patients of skin bleeding (59.0%), 144 patients of mucosal bleeding (34.1%), and 11 patients of organ bleeding (2.6%), of which 2 patients were severe bleeding. The two bleeding scoring scales were both negatively correlated with platelet counts in children with ITP (r s=-0.5032, r s=-0.6084) and no correlation with the stage of pediatric ITP(P >0.05). The 2019 Pediatric ITP Scale had good consistency with the 2013 ITP-BAT (r s=0.7638). The average time required for the 2019 Pediatric ITP Scale was 88.64 (40-181) seconds, which was lower than that required for the 2013 ITP-BAT 104.12 (47-285) seconds (Z =17.792, P < 0.001). The 2019 Pediatric ITP Scale can well reflect the treatment of pediatric ITP. There were statistically significant differences in platelet count before treatment and after treatment at 48 h and one week among steroid group, IVIG group and steroid combined with IVIG group ( P < 0.05). There were also statistically significant differences in the score of the 2019 Pediatric ITP Scale before treatment and after treatment at one week among the three groups ( P < 0.05).
CONCLUSION: The 2019 Pediatric ITP Scale has good consistency and sensitivity in clinical application, and it takes less time to complete than the 2013 ITP-BAT, this scale can be used as an effective tool for disease assessment and efficacy determination in pediatric primary immune thrombocytopenia.
BACKGROUND: Low operator and institutional volume is associated with poorer procedural and long-term clinical outcomes in patients treated with percutaneous coronary interventions (PCI). This study was aimed at evaluating the relationship between operator volume and procedural outcomes of patients treated with PCI for chronic total occlusion (CTO).
METHODS: Data were obtained from the national registry of percutaneous coronary interventions (ORPKI) collected from January 2014 to December 2020. The primary endpoint was a procedural success, defined as restoration of thrombolysis in myocardial infarction (TIMI) II/III flow without in-hospital cardiac death and myocardial infarction, whereas secondary endpoints included periprocedural complications.
RESULTS: Data of 14,899 CTO-PCIs were analyzed. The global procedural success was 66.1%. There was a direct relationship between the annual volume of CTO-PCIs per operator and the procedural success (OR: 1.006 [95% CI: 1.003-1.009]; P<0.001). The nonlinear relationships of annualized CTO-PCI volume per operator and adjusted outcome rates revealed that operators performing 40 CTO cases per year had the best procedural outcomes in terms of technical success (TIMI flow II/III after PCI), coronary artery perforation rate and any periprocedural complications rate (P<0.0001). Among the other factors associated with procedural success, the following can be noted: multi-vessel, left main coronary artery disease (as compared to single-vessel disease), the usage of rotablation as well as PCI within bifurcation.
CONCLUSIONS: High-volume CTO operators achieve greater procedural success with a lower frequency of periprocedural complications. Higher annual caseload might increase the overall quality of CTO-PCI.
A sample of 20 children with Type 1 Diabetes and their caregivers will be asked to stay after their diabetes clinic appointment to complete enrollment, or they may choose to come back for a study visit. Trained study staff will describe the study in detail to interested families. They will be encouraged to ask questions before giving consent. After obtaining informed consent/assent, children and caregivers will schedule time for a neurocognitive assessment and neuroimaging assessment. Children and caregivers will complete assessments again approximately 12 months later.
The present invention comprises methods for inhibiting the activity of a matrix metalloproteinase in the skin including topical application to the skin surface by a composition including a ratio effective to the synergistic action of the amount of a hydroxamic acid, a salt thereof, and/or a complex thereof and the amount of glycol. In some embodiments, the ratio of the weight percent of a hydroxamic acid, a salt thereof, and/or a complex thereof to the weight percent of glycol is selected from the ratio of approximately 1 to approximately 1.4; approximately 1 to approximately 3; and approximately 1 to approximately 5, (with respect to the weight of the total composition). In addition, the present invention comprises related methods including methods for preventing or reducing the appearance of aging on the skin surface, wherein the method comprises topical application to the skin surface by the composition comprising the ratio effective to the synergistic action of the amount of a hydroxamic acid, a salt thereof, and/or a complex thereof and the amount of glycol. Methods for increasing the enzymatic inhibition potential of glycol comprise a step of combining at least one glycol with the amount of a hydroxamic acid, a salt thereof, and/or a complex thereof at a ratio effective to the synergistic action to form a synergistic mixture, wherein the enzymatic inhibition potential of the synergistic mixture is greater than that of the glycol alone or the hydroxamic acid alone. Within the scope of the present invention, aging prevention compositions are contemplated, which inhibit the activity of matrix metalloproteinases (MMPs) in the skin, including a ratio effective to the synergistic action of the amount of a hydroxamic acid, a salt thereof, and/or a complex thereof and the amount of glycol. In some embodiments, the ratio is selected from the weight percent of approximately 1: 1: 4, approximately 1: 3; and approximately 1 to 5 (with respect to the weight of the total composition).
Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be \>= 5 days between each dose.
PURPOSE:To obtain a processed red blood-corpuscle with added stability while the natural antigen property thereof is maintained, by processing a natural red blood-corpuscle at moderate temperatures with a fixing agent of low concentration. CONSTITUTION:It becomes possible to obtain such processed red blood-corpuscle that maintains its natural antigen property, and has added stability, by processing a natural red blood corpuscle by a fixing agent of low concentration. The natural red blood-corpuscle referred to above is a red blood-corpuscle of a man, cow or sheep, etc. and is raw without being processed by, for example, fixing treatment or treatment with the use of a reducing agent. The natural red blood-corpuscle is processed in a solution of a fixing agent in a predetermined range of concentration generally at 4-40 deg.C or so, preferably at approximately 20-30 deg.C for about 1-10min. As a result, the processed red blood- corpuscle represents no inferior to-be-coagulated property and remarkably superior stability in preservation to the raw red blood-corpuscle, which is, therefore, particularly useful for detection of an antibody of a blood group.
Depending on when the subject is enrolled into the study, the following will be completed: The subject will receive a single injection of SAV or placebo (an inactive substance) in the deltoid muscle of the upper arm. The subject will then be watched for 30 minutes after vaccination to monitor for allergic reactions. The subject will be asked to visit the study doctor either 6 or 9 times during the 3-month study period. Once enrolled, the subject will have blood drawn before receiving the vaccine (baseline) and up to 7 times after that at each of the required visits. The blood will be used for tests and/or for testing the subject's body's immune response to the SAV, to see if the subjects have developed immunity to S. aureus and if immunity continues up to 84 days. A Vaccination Report Card (VRC) will be provided to all participants. The participant will be asked to record oral temperatures and any reactions that occur at the SAV injection site every day for 5 days after vaccination. The participant will also be asked to record any physical adverse effects that they may experience, including headaches, nausea, muscle pain or aches, and fatigue every day for 14 days after vaccination. In additional all medications (including over the counter medications) taken during the 14 days post vaccination will be recorded and the VRC will be returned to the research staff after 14 days.
FIELD: organic chemistry, amino acids, pharmacy. SUBSTANCE: invention describes ester of the general formula (I)  , its N-oxide form, pharmaceutically acceptable additive salt or its stoichiometrically isomeric form where A-B- form bivalent radical of the formula: -N=CH- (a); -CH=N- (b) where one hydrogen atom in radicals (a) and (b) can be substituted with C 1-6 -alkyl radical; L means acyl moiety of amino acid; D means radical of the formula   or   where X means N atom; R 1  means halogen atom; R 2  means hydrogen or halogen atom. Invention describes also methods of synthesis of compounds of the formula (I), pure enantiomeric form of intermediate compound, enantiomeric mixture of intermediate substances, pharmaceutical composition exhibiting antifungal activity of wide spectrum of effect and method of pharmaceutical composition preparing. Invention provides synthesis of new compounds eliciting useful biological properties. EFFECT: improved methods of synthesis and preparing, valuable medicinal and biological properties of compounds. 18 cl, 10 tbl
The present invention discloses a Chinese medicine composition and a preparation method thereof, the Chinese medicine composition is used for treating fever, pharyngitis and common cold caused by the viral infection of upper respiratory tracts. The Chinese medicine composition is mainly prepared from isatis root, honeysuckle stem, vietnamese sophora root, paris root, heartleaf houttuynia herb, male fern rhizome, sweet wormwood herb and dahurian angelica. The Chinese medicine composition has the following preparation method: the raw materials are decocted with water; the decoction liquid is combined and filtered; the decoction liquid is condensed into paste with 1.05 to 1.15 of relative density; after the temperature is cooled at the room temperature, alcohol with 50 to 70% of alcohol content is filled, is uniformly blended and is stored at cold temperature; supernatant liquid is extracted and filtered to make the filter liquid condensed into extract with 1.20 to 1.40 (40 to 60 DEG C) of relative density, and after the extract is extracted, an excipient accepted by pharmacy is directly or indirectly filled by a conventional working procedure to be manufactured into preparations, such as tablets, oral medicinal liquid, capsules, granules, injections, etc. which are clinically accepted. The Chinese medicine composition has very good functions on clearing away heat and toxic materials, treating heating pharyngitis, common cold, etc. caused by the viral infection of upper respiratory tracts.
Nitroglycerine, the classic drug for myocardial ischemia, has been used over a century. By providing exogenous No., it alleviates the myocardial ischemia and is mainly used in the first aid of myocardial ischemia. The 4-Medicinal-Plant-Derived Coronary Blood Flow enhancing Agent is the result of strictly controlled processing procedures including the followings: extracting with Carbon Dioxide Supercritical Fluid; WLD resin adsorbing, eluting, separating and purifying; high performance liquid chromatography and fingerprint analysis to ensure the balanced and stable quality. Pharmacological experiments indicated that it increased coronary blood flow, lowered peripheral vascular resistance, regulated myocardial oxygen supply-demand balance and decreased the oxygen consumption index as well as myocardial oxygen consumption. It takes effect in a way different from Nitroglycerine. This agent can be used for the prevention and treatment of myocardial ischemia, coronary heart disease and angina pectoris.
Before starting the process, participants will be informed about the study and their verbal and written consent will be obtained. Participants in the virtual reality group will be shown and introduced to virtual reality glasses before the procedure. After the woman goes to the examination table and takes the appropriate position for the pap smear procedure, virtual reality glasses will be put on the woman by the researcher. The selected video will be played until the Pap smear process is completed. (https://www.youtube.com/watch?v=6ud18oSuCiY\&t=30s). When the Pap smear is finished, the glasses will be removed and the woman will be helped to get up from the examination table. In this process, no form will be filled until the participant woman gets dressed and takes the ready position. Thus, the privacy of women will be protected and there will be no violation of ethical rights.
A genome-wide association study (GWAS) is a powerful tool in investigating genetic contribution, which is a crucial factor in the development of complex multifactorial diseases, such as type 2 diabetes mellitus. Type 2 diabetes mellitus is a major healthcare burden in the Western Pacific region; however, there is limited availability of genetic-associated data for type 2 diabetes in Southeast Asia, especially among the Kinh Vietnamese population. This lack of information exacerbates global healthcare disparities. In this study, 997 Kinh Vietnamese individuals (503 with type 2 diabetes and 494 controls) were prospectively recruited and their clinical and paraclinical information was recorded. DNA samples were collected and whole genome genotyping was performed. Standard quality control and genetic imputation using the 1000 Genomes database were executed. A polygenic risk score for type 2 diabetes was generated in different models using East Asian, European, and mix ancestry GWAS summary statistics as training datasets. After quality control and genetic imputation, 107 polymorphisms reached suggestive statistical significance for GWAS (≤5 × 10-6) and rs11079784 was one of the potential markers strongly associated with type 2 diabetes in the studied population. The best polygenic risk score model predicting type 2 diabetes mellitus had AUC = 0.70 (95% confidence interval = 0.62-0.77) based on a mix of ancestral GWAS summary statistics. These data show promising results for genetic association with a polygenic risk score estimation in the Kinh Vietnamese population; the results also highlight the essential role of population diversity in a GWAS of type 2 diabetes mellitus.
The recommended dosage of SUSTOL is 10 mg administered subcutaneously. Administer SUSTOL in combination with dexamethasone at least 30 minutes before the initiation of MEC or AC combination chemotherapy. Administer SUSTOL on Day 1 of chemotherapy and not more frequently than once every 7 days because of the extended-release properties of the formulation.

For patients receiving MEC, the recommended dexamethasone dosage is 8 mg intravenously on Day 1. For patients receiving AC combination chemotherapy regimens, the recommended dexamethasone dosage is 20 mg intravenously on Day 1, followed by 8 mg orally, twice a day, on Days 2, 3 and 4.

If SUSTOL is administered with an NK1 receptor antagonist, see the prescribing information of the NK1 receptor antagonist for the recommended dexamethasone dosage.
The invention provides an antioxidant active peptide, which is selected from one or more of the following sequences: FYSLHTF, the amino acid sequence is shown as SEQ ID NO. 1; SSGHTLPAGV, the amino acid sequence is shown in SEQ ID NO. 2; TFQGPPHG, the amino acid sequence is shown in SEQ ID NO. 3; VLFSNY, the amino acid sequence is shown as SEQ ID NO. 4; VYGYADK, the amino acid sequence is shown in SEQ ID NO. 5; YTPEYQTK has an amino acid sequence shown in SEQ ID NO. 6. The active peptide provided by the invention has antioxidant activity, and can be used as a functional active factor for developing foods, health-care products and medicines with antioxidant effect. The active peptides of the invention may be present as a single active ingredient or as a synergistic effect of one of the active ingredients with the other active ingredients.
A suspension comprising microgranules having bead sizes in the range of 100 to 1200 microns of a benzimidazole derivative suspended in a triglyceride ester of a fatty acid where the suspension is stable for at least 1 month. Preferably the benzimidazole derivative is provided in the form of enteric coated beads. The enteric coating may comprise one or more layers selected from a disintegrant layer, a sealing later, and a controlled release layer. Preferably the benzimidazole derivative is formed on a sugar core. Preferably the benzimidazole derivative is a proton pump inhibitor, and is preferably pantoprazole, lansoprazole, rabeprazole or especially omeprazole. Preferably the fatty acid is a C8-10 fatty acid. The suspension may comprise a preservative, preferably potassium sorbate. The suspension may comprise one or more rafting agents, preferably alginic acid. The suspension may be used in the treatment of dyspepsia, peptic ulcer disease, gastritis, gastroesophagael reflux disease, laryngopharyngeal reflux, gastric and duodenum ulceration, and Zollinger-Ellison syndrome.